Skip to main content
Toggle navigation
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
G
Garhyan, Arnay
Park Tudor High School
PI-117
-
DEVELOPMENT OF POPULATION PHARMACOKINETICS MODEL AND R-SHINY SIMULATION PLATFORM FOR MOXIFLOXACIN IN NON-HUMAN PRIMATES
Arnay Garhyan
Favorite
Gastonguay, Marc
Metrum Research Group
PII-063
-
COST EFFECTIVENESS OF INDIVIDUALIZED DOSING FOR A HYPOTHETICAL NEW DRUG IN ATOPIC DERMATITIS: A PHARMACOMETRIC-PHARMACOECONOMIC SIMULATION STUDY.
Marc Gastonguay
Favorite
Gawronski, Brian
University of Florida
LB-007
-
GENETIC POLYMORPHISMS IN SLC5A2 ARE ASSOCIATED WITH CLINICAL OUTCOMES AND SGLT2I RESPONSE IN HEART FAILURE PATIENTS.
Brian Gawronski
Favorite
PII-044
-
DEMOGRAPHICS AND UTILIZATION OF MEDICATIONS WITH PHARMACOGENETICS GUIDELINES IN THE TRIAL OF PREMPTIVE PHARMAGOGENETICS IN UNDERSERVED PATIENTS (TOPP UP)
Brian Gawronski
Favorite
Gershuny, Victoria
U.S. Food and Drug Administration
PII-107
-
CLINICAL STUDY TO INVESTIGATE THE EFFECT OF ADMINISTRATION OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND AN OPIOID ON VENTILATION.
Victoria Gershuny
Favorite
Ghasemi, Mohammad
Arcus Biosciences
PI-059
-
CASDATIFAN (AB521) PHARMACOKINETICS IS SIMILAR WHEN ADMINISTERED AS CAPSULES OR TABLETS AND IS UNAFFECTED BY FOOD
Mohammad Ghasemi
Favorite
Gillis, Nancy
Moffitt Cancer Center and Research Institute
PII-028
-
CLONAL HEMATOPOIESIS AS A PRECISION MEDICINE BIOMARKER FOR PATIENTS WITH CANCER
Nancy Gillis
Favorite
Gong, Xiaohua
Incyte Corporation
PI-029
-
EFFECT OF HEPATIC FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ
Xiaohua Gong
Favorite
PII-029
-
EFFECT OF RENAL FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ
Xiaohua Gong
Favorite
Gooden, Felicia
University of Cincinnati/Cincinnati Children's Hospital Medical Center
PI-048
-
GREATER METHOTREXATE EXPOSURE IN HSLCO1B1*14 TRANSGENIC MICE AS THE RESULT OF PHARMACOGENOMIC GUIDED-DOSING NORMALIZES THERAPEUTIC RESPONSE
Felicia Gooden
Favorite
Goti, Vineet
Bristol Myers Squibb
PI-072
-
LIKELY INHIBITION OF NON-CYP450 PATHWAYS BY BMS-986196 LEADS TO DOUBLING OF EE EXPOSURE.
Vineet Goti
Favorite
Grant, Caroline
Mayo Clinic
OAII-002
-
EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA
Caroline Grant
Favorite
PI-075
-
MODEL-BASED META-ANALYSIS OF PLACEBO-RESPONSE FOR MONTHLY MIGRAINE DAYS IN MIGRAINE PREVENTION CLINICAL TRIALS FROM LITERATURE
Caroline Grant
Favorite
PT-003
-
EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA
Caroline Grant
Favorite
Gronich, Naomi
Faculty of Medicine - Technion - Israel Institute of Technology; Clalit Health Services
E-001
-
MEDICATIONS AND ACUTE HEMOLYSIS IN G6PD-DEFICIENT PATIENTS A REAL-WORLD STUDY. Received February 25, 2024; accepted May 20, 2024. doi:10.1002/cpt.3333
Naomi Gronich
Favorite
LB-002
-
ASSOCIATION BETWEEN TREATMENT FOR MULTIPLE SCLEROSIS IN PREGNANCY AND PRECONCPETION PERIODS AND FETAL OUTCOMES - A REAL-WORLD RETROSPECTIVE COHORT STUDY
Naomi Gronich
Favorite
Guo, Cen Cathy
Pfizer
LB-005
-
TALAZOPARIB FORMULATION BRIDGING IN CANCER PATIENTS-CHALLENGES AND THE CRITICAL ROLE OF MIDD IN APPROVAL DESPITE FAILED BIOEQUIVALENCE
Cen Cathy Guo
Favorite
Guttendorf, Robert
Aclairo Pharmaceutical Development Group, Inc.
PI-106
-
SAFETY AND PHARMACOKINETICS OF DF-003, A TARGETED, FIRST-IN-CLASS ALPHA-KINASE 1 INHIBITOR FOR TREATMENT OF THE RARE GENETIC DISEASE, ROSAH SYNDROME.
Robert Guttendorf
Favorite